---
title: "HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296422700.md"
description: "Hengrui Pharma reported a 0.3% YoY increase in H1 2026 net profit to RMB4.465 billion, despite a 1.9% revenue decline. Innovative drug sales rose 16.4%, and R&D investment increased 19%. The company plans to repurchase A-shares worth RMB1-2 billion for employee incentives. Shares fell over 7% amid trading activity."
datetime: "2026-08-20T01:56:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296422700.md)
  - [en](https://longbridge.com/en/news/296422700.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296422700.md)
---

# HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%

HENGRUI PHARMA (01276.HK) \-4.250 (-7.734%) Short selling $36.95M; Ratio 16.359% announced its interim results for the six months ended June 2026. Revenue amounted to RMB15.456 billion, down 1.9% YoY. Net profit rose 0.3% YoY to RMB4.465 billion, while EPS was RMB0.68. No interim dividend was declared.  

  
During the period, product sales revenue increased 1.9% YoY to RMB13.948 billion. Innovative drug sales revenue rose 16.4% to RMB8.809 billion, accounting for 63.2% of pharmaceutical sales revenue. Among innovative drug sales revenue, revenue from anti-tumor products increased 2.6% to RMB6.265 billion, representing 71.1% of total innovative drug sales revenue. R&D investment rose 19% to RMB4.605 billion, of which expensed R&D investment increased 8.2% to RMB3.493 billion.

Looking ahead to 2H26, the company expects multiple growth drivers to gradually generate synergies and is optimistic that innovative drug revenue will achieve rapid growth.

In addition, the company announced plans to repurchase A-shares worth between RMB1 billion and RMB2 billion. The maximum repurchase price will not exceed RMB90.85 per share, and all repurchased A-shares will be used for employee share ownership plans or equity incentives.

HENGRUI PHARMA is currently trading at RMB50.85, down 7.46%, with turnover of 5.7455 million shares involving RMB290 million. (jl)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-19 16:25.)

AASTOCKS Financial News

### Related Stocks

- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)
- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)

## Related News & Research

- [Hengrui Pharma Advances 2026 Employee Stock Ownership Plan Using Existing A Shares](https://longbridge.com/en/news/296370263.md)
- [Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78](https://longbridge.com/en/news/296368941.md)
- [Granite REIT declares August distribution of CDN $0.3 per unit](https://longbridge.com/en/news/296145681.md)
- [Mondelez declares Q3 2026 distribution of R$ 0.3 per unit, payable Oct. 20](https://longbridge.com/en/news/296392808.md)
- [Jiangsu Hengrui files HKEX next-day disclosure return after share repurchase for treasury shares](https://longbridge.com/en/news/295383271.md)